[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
3. Moore AJ, Parker RJ, Wiggins J: Malignant mesothelioma. Orphanet J Rare Dis; 2008;3:34
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma.
  • Malignant mesothelioma is a fatal asbestos-associated malignancy originating from the lining cells (mesothelium) of the pleural and peritoneal cavities, as well as the pericardium and the tunica vaginalis.
  • Pleural malignant mesothelioma is the most common form of mesothelioma.
  • Mesothelioma is directly attributable to occupational asbestos exposure with a history of exposure in over 90% of cases.
  • There is also evidence that mesothelioma may result from both para-occupational exposure and non-occupational "environmental" exposure.
  • Idiopathic or spontaneous mesothelioma can also occur in the absence of any exposure to asbestos, with a spontaneous rate in humans of around one per million.
  • A combination of accurate exposure history, along with examination radiology and pathology are essential to make the diagnosis.
  • Distinguishing malignant from benign pleural disease can be challenging.
  • The most helpful CT findings suggesting malignant pleural disease are 1) a circumferential pleural rind, 2) nodular pleural thickening, 3) pleural thickening of > 1 cm and 4) mediastinal pleural involvement.
  • Involvement of a multidisciplinary team is recommended to ensure prompt and appropriate management, using a framework of radiotherapy, chemotherapy, surgery and symptom palliation with end of life care.
  • Life expectancy in malignant mesothelioma is poor, with a median survival of about one year following diagnosis.
  • [MeSH-major] Mesothelioma / diagnosis. Mesothelioma / pathology. Pleural Neoplasms / diagnosis. Pleural Neoplasms / pathology
  • [MeSH-minor] Humans. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4225-31 [16857795.001]
  • [Cites] Semin Diagn Pathol. 2006 Feb;23(1):56-60 [17044196.001]
  • [Cites] Orphanet J Rare Dis. 2006;1:44 [17090323.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(1):CD005574 [17253564.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Apr;19(3):182-7 [17359904.001]
  • [Cites] Clin Chem. 2007 Apr;53(4):666-72 [17289801.001]
  • [Cites] J Thorac Oncol. 2006 May;1(4):289-95 [17409872.001]
  • [Cites] Exp Anim. 2007 Apr;56(2):155-9 [17460361.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):2928-35 [17504993.001]
  • [Cites] Curr Opin Pulm Med. 2007 Jul;13(4):339-443 [17534183.001]
  • [Cites] Radiother Oncol. 2007 Jul;84(1):18-22 [17588698.001]
  • [Cites] Oncologist. 2007 Jul;12(7):850-63 [17673616.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1196-202 [17429100.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1366-74 [17674974.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):350-7 [17467922.001]
  • [Cites] Thorax. 2007 Nov;62 Suppl 2:ii1-ii19 [17965072.001]
  • [Cites] Eur Respir J. 2007 Nov;30(5):1021 [17978160.001]
  • [Cites] Occup Med (Lond). 2007 Dec;57(8):564-8 [17675661.001]
  • [Cites] Ann Thorac Surg. 2008 Jan;85(1):265-72; discussion 272 [18154821.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):370-3 [18156144.001]
  • [Cites] Mayo Clin Proc. 2008 Feb;83(2):235-50 [18241636.001]
  • [Cites] Ann Thorac Surg. 2008 Mar;85(3):1049-55 [18291195.001]
  • [Cites] Arch Pathol Lab Med. 2008 Mar;132(3):397-401 [18318582.001]
  • [Cites] J Thorac Cardiovasc Surg. 2008 Mar;135(3):620-6, 626.e1-3 [18329481.001]
  • [Cites] Lung Cancer. 2008 Mar;59(3):411-20 [18061303.001]
  • [Cites] Curr Opin Pulm Med. 2008 Jul;14(4):303-9 [18520263.001]
  • [Cites] Regul Toxicol Pharmacol. 2008 Oct;52(1 Suppl):S223-31 [18022298.001]
  • [Cites] Occup Med (Lond). 2005 Mar;55(2):79-87 [15757980.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Eur J Cardiothorac Surg. 2000 Aug;18(2):143-6 [10925221.001]
  • [Cites] J Clin Oncol. 2000 Dec 1;18(23):3912-7 [11099320.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Oct;122(4):788-95 [11581615.001]
  • [Cites] Toxicol Lett. 2002 Feb 28;127(1-3):251-7 [12052665.001]
  • [Cites] Lung Cancer. 2002 Nov;38(2):111-21 [12399121.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):606-16 [12573747.001]
  • [Cites] Thorax. 2003 May;58 Suppl 2:ii29-38 [12728148.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Ann Diagn Pathol. 2003 Oct;7(5):321-32 [14571437.001]
  • [Cites] Lancet. 2003 Nov 15;362(9396):1612-6 [14630441.001]
  • [Cites] Radiographics. 2004 Jan-Feb;24(1):105-19 [14730040.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):257-60 [14760119.001]
  • [Cites] Thorax. 2004 Feb;59(2):144-8 [14760156.001]
  • [Cites] Chest. 2004 Feb;125(2):489-93 [14769729.001]
  • [Cites] Cochrane Database Syst Rev. 2004;(1):CD002916 [14973997.001]
  • [Cites] Int J Occup Environ Health. 2004 Jan-Mar;10(1):26-39 [15070023.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Jul;128(1):138-46 [15224033.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Aug 15;170(4):377-82 [15142871.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1406-12 [15319247.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1157-66 [15451223.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1183-5 [15451229.001]
  • [Cites] Q J Med. 1976 Jul;45(179):427-49 [948545.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Jan;8(1):19-25 [6174494.001]
  • [Cites] Acta Clin Belg. 1989;44(3):199-201 [2816228.001]
  • [Cites] AJR Am J Roentgenol. 1990 Mar;154(3):487-92 [2106209.001]
  • [Cites] Am J Clin Oncol. 1990 Feb;13(1):4-9 [1689538.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Mar;20(3):433-8 [1995528.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1991 Nov;3(6):315-7 [1720658.001]
  • [Cites] Australas Radiol. 1994 Aug;38(3):212-4 [7524472.001]
  • [Cites] Lancet. 1995 Mar 4;345(8949):535-9 [7776771.001]
  • [Cites] J Comput Assist Tomogr. 1995 May-Jun;19(3):370-4 [7790544.001]
  • [Cites] Chest. 1995 Sep;108(3):754-8 [7656629.001]
  • [Cites] Chest. 1995 Oct;108(4):1122-8 [7555126.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1995;7(5):317-8 [8580058.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40 [8552591.001]
  • [Cites] Eur Respir J. 1996 Jun;9(6):1206-10 [8804939.001]
  • [Cites] Ann Surg. 1996 Sep;224(3):288-94; discussion 294-6 [8813257.001]
  • [Cites] Thorax. 1997 Jun;52(6):507-12 [9227715.001]
  • [Cites] Eur J Cancer Prev. 1997 Apr;6(2):162-6 [9237066.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 1997 Oct;9(4):367-72 [9352954.001]
  • [Cites] Thorax. 1997 Aug;52 Suppl 3:S52-7 [9381428.001]
  • [Cites] Ann Oncol. 1998 Mar;9(3):269-73 [9602260.001]
  • [Cites] Respir Med. 1998 Apr;92(4):691-2 [9659538.001]
  • [Cites] Chest. 1998 Sep;114(3):713-22 [9743156.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4505-9 [9788590.001]
  • [Cites] Radiology. 1999 Jan;210(1):277-81 [9885620.001]
  • [Cites] Occup Environ Med. 1999 Jan;56(1):51-8 [10341747.001]
  • [Cites] Br J Ind Med. 1960 Oct;17:260-71 [13782506.001]
  • [Cites] Br J Cancer. 2005 Feb 14;92(3):587-93 [15668716.001]
  • [Cites] Eur J Surg Oncol. 2005 Apr;31(3):314-20 [15780570.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2602-9 [15805256.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S109-11 [15950789.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S37-40 [15950799.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6881-9 [16192580.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1564-73 [16221779.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Jan;29(1):14-9 [16343925.001]
  • [Cites] Clin Imaging. 2006 May-Jun;30(3):177-80 [16632152.001]
  • [Cites] Am J Respir Crit Care Med. 2006 May 15;173(10):1155-60 [16456138.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):640-5 [16751058.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(3):CD003880 [16856023.001]
  • (PMID = 19099560.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 93
  • [Other-IDs] NLM/ PMC2652430
  •  go-up   go-down


Advertisement
4. Papi M, Genestreti G, Tassinari D, Lorenzini P, Serra S, Ricci M, Pasquini E, Nicolini M, Pasini G, Tamburini E, Fattori PP, Ravaioli A: Malignant pericardial mesothelioma. Report of two cases, review of the literature and differential diagnosis. Tumori; 2005 May-Jun;91(3):276-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for pericardial mesothelioma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pericardial mesothelioma. Report of two cases, review of the literature and differential diagnosis.
  • Malignant pericardial mesothelioma is an uncommon variety of a primary malignant cardio-pericardial tumor and it is a highly lethal and fortunately rare cardiac neoplasm.
  • The presentation of pericardial mesothelioma is aspecific and pathologically mesothelioma is not the most common among primary tumors of the pericardium.
  • Antemortem diagnosis is difficult and distant metastases are extremely rare.
  • Radical surgery can be used to treat localized mesothelioma.
  • The treatment for advanced primary pericardial mesothelioma is usually palliative because the tumor is resistant to radiotherapy and chemotherapy.
  • In this paper we report two cases of patients with primary mesothelioma of the pericardium without a definite history of asbestos exposure.
  • [MeSH-major] Heart Neoplasms / pathology. Mesothelioma / pathology. Pericardium / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Humans. Male. Prognosis. Survival

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206657.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


5. Balli A, Lachat M, Gerber B, Baumgartner C, Glaus T: [Cardiac tamponade due to pericardial mesothelioma in an 11-year-old dog: diagnosis, medical and interventional treatments]. Schweiz Arch Tierheilkd; 2003 Feb;145(2):82-7
MedlinePlus Health Information. consumer health - Pericardial Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cardiac tamponade due to pericardial mesothelioma in an 11-year-old dog: diagnosis, medical and interventional treatments].
  • Pericardial effusion recurred soon after pericardiocenteses, prescription of colchizine and again after balloon pericardiotomy.
  • After partial pericardectomy by thoracoscopy and after obtaining a histological diagnosis of mesothelioma adjuvant intracavitary chemotherapy using cisplatin was performed.
  • Already one week later the dog developed marked dyspnea due to severe pleural effusion.
  • Despite extensive treatments life span from initial presentation to euthanasia was only 5 months.
  • Necropsy revealed extensive mesothelioma metastases covering the whole pleura, epicardium and remaining pericardium.
  • Diagnostic and therapeutic aspects of (recurrent) pericardial effusion are discussed based on this case.
  • [MeSH-major] Cardiac Tamponade / veterinary. Dog Diseases / diagnosis. Heart Neoplasms / veterinary. Mesothelioma / veterinary
  • [MeSH-minor] Animals. Diagnosis, Differential. Dogs. Euthanasia, Animal. Fatal Outcome. Male. Pericardial Effusion / etiology. Pericardial Effusion / therapy. Pericardial Effusion / veterinary. Pericardiectomy / veterinary. Pericardiocentesis / veterinary. Pleural Effusion, Malignant / etiology. Pleural Effusion, Malignant / therapy. Pleural Effusion, Malignant / veterinary. Recurrence

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12649954.001).
  • [ISSN] 0036-7281
  • [Journal-full-title] Schweizer Archiv für Tierheilkunde
  • [ISO-abbreviation] Schweiz. Arch. Tierheilkd.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


6. Debourdeau P, Gligorov J, Teixeira L, Aletti M, Zammit C: [Malignant cardiac tumors]. Bull Cancer; 2004 Nov;91 Suppl 3:136-46

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant cardiac tumors].
  • The various frequencies of primary and secondary malignant tumors vary from report to report, approximately 1% in most autopsy series and 4% in cancer patient's autopsies.
  • Apart from primary pericardial mesothelioma, primary cardiac tumors are high-grade sarcomas with a high metastatic potency that often becomes evident early after surgery.
  • Diagnosis is actually made easier with cardiac echography.
  • Cardiac RMI is helpful to estimate vessels and pericardium involvement.
  • Due to its poor prognosis, treatment of cardiac metastases is restricted to best supportive care.
  • For primary cardiac neoplasms, surgery must be carefully discussed because operative intervention is often followed by rapid widespread metastases that adjuvant chemotherapy cannot avoid in most cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15899620.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 53
  •  go-up   go-down


7. Antman K, Hassan R, Eisner M, Ries LA, Edwards BK: Update on malignant mesothelioma. Oncology (Williston Park); 2005 Sep;19(10):1301-9; discussion 1309-10, 1313-6
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on malignant mesothelioma.
  • About 85% of mesotheliomas arise in the pleura, about 91% in the peritoneum, and a small percentage in the pericardium or tunica vaginalis testis.
  • Multicystic mesotheliomas and well-differentiated papillary mesotheliomas are associated with long survival in the absence of treatment and should be excluded from clinical trials intended for the usual rapidly lethal histologic variants of the disease.
  • Recent randomized trials have shown significant improvement in time to progression and survival for the addition of new antifolates to platinum-based chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / diagnosis. Mesothelioma / epidemiology. Mesothelioma / pathology. Mesothelioma / therapy
  • [MeSH-minor] Asbestos / adverse effects. Folic Acid Antagonists / administration & dosage. Folic Acid Antagonists / therapeutic use. Heart Neoplasms / pathology. Humans. Incidence. Male. Neoplasm Staging. Peritoneal Neoplasms / pathology. Platinum Compounds / administration & dosage. Platinum Compounds / therapeutic use. Pleural Neoplasms / pathology. Prognosis. Quality of Life / psychology. Survival Analysis. Testicular Neoplasms / pathology. Treatment Outcome. United States / epidemiology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16285225.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Folic Acid Antagonists; 0 / Platinum Compounds; 1332-21-4 / Asbestos
  •  go-up   go-down


8. Maruyama R, Sakai M, Nakamura T, Suemitsu R, Okamoto T, Wataya H, Nishiyama K, Kamei T, Ichinose Y: Triplet chemotherapy for malignant pericardial mesothelioma: a case report. Jpn J Clin Oncol; 2006 Apr;36(4):245-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triplet chemotherapy for malignant pericardial mesothelioma: a case report.
  • Malignant pericardial mesothelioma (MPM) is a relatively rare neoplasm in Japan, and no standard treatment regimens have been established for this disease.
  • A 47-year-old woman with MPM presenting with cardiac tamponade was treated using four cycles of chemotherapy consisting of cisplatin (CDDP) 40 mg/m2, gemcitabine (GEM) 800 mg/m2 and vinorelbine (VNR) 20 mg/m2 on days 1 and 8 every 4 weeks after pericardial drainage alone.
  • The diagnosis of MPM was confirmed by an immunohistochemical procedure using either positive or negative markers of malignant mesothelioma in addition to conventional cytological examinations using pericardial effusion.
  • The patient has returned to her usual activities and has remained well for 24 months after the last chemotherapy without any evidence of disease progression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Heart Neoplasms / drug therapy. Mesothelioma / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drainage. Drug Administration Schedule. Female. Humans. Middle Aged. Neutropenia / chemically induced. Pericardial Effusion / pathology. Remission Induction. Survivors. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16533802.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


9. Molina Garrido MJ, Mora Rufete A, Rodríguez-Lescure A, Cascón Pérez JD, Ardoy F, Guillén Ponce C, Carrato Mena A: Recurrent pericardial effusion as initial manifestation of primary diffuse pericardial malignant mesothelioma. Clin Transl Oncol; 2006 Sep;8(9):694-6
MedlinePlus Health Information. consumer health - Pericardial Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent pericardial effusion as initial manifestation of primary diffuse pericardial malignant mesothelioma.
  • The case of a 61-year-old woman who presented a recurrent symptomatic pericardial effusion and a malignant cardiac tamponade six months prior to the detection of a mediastinal anterior mass is described.
  • Diffuse malignant pericardial mesothelioma was diagnosed after mediastinal mass biopsy.
  • The patient underwent further oncological evaluation followed by chemotherapy.
  • [MeSH-major] Heart Neoplasms / diagnosis. Mesothelioma / diagnosis. Pericardial Effusion / etiology. Pericardium

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cardiovasc Clin. 1973;5(1):207-38 [4589961.001]
  • [Cites] Am Heart J. 1988 Jun;115(6):1321-2 [3376853.001]
  • [Cites] Med Pediatr Oncol. 1995 Mar;24(3):208-12 [7838044.001]
  • [Cites] J Cardiovasc Surg (Torino). 1994 Jun;35(3):261-7 [8040178.001]
  • [Cites] Cardiovasc Clin. 1976;7(3):257-69 [1000541.001]
  • [Cites] Am J Cardiol. 1979 Nov;44(6):1110-4 [495505.001]
  • [Cites] Pathol Int. 1995 Aug;45(8):622-5 [7496510.001]
  • [Cites] Am Heart J. 1987 Mar;113(3):785-90 [3548297.001]
  • [Cites] Am Heart J. 1986 May;111(5):986-8 [3706117.001]
  • [Cites] Br J Dis Chest. 1983 Oct;77(4):321-43 [6357260.001]
  • (PMID = 17005474.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


10. Weder W, Kestenholz P, Taverna C, Bodis S, Lardinois D, Jerman M, Stahel RA: Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol; 2004 Sep 1;22(17):3451-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
  • PURPOSE: To investigate neoadjuvant chemotherapy with cisplatin and gemcitabine followed by extrapleural pneumonectomy with or without radiation therapy in patients with potentially resectable malignant pleural mesothelioma (MPM).
  • Neoadjuvant chemotherapy consisted of three cycles of cisplatin 80 mg/m2 on day 1 and gemcitabine 1,000 mg/m2 on days 1, 8, and 15, given every 28 days.
  • Surgery had to consist of a complete extrapleural pneumonectomy, including resection of pericardium and diaphragm.
  • According to the European Organization for Research and Treatment of Cancer prognostic score, two patients were in the good prognosis group, and 17 patients were in the poor prognosis group.
  • The response rate to neoadjuvant chemotherapy was 32%.
  • The median survival time was 23 months.
  • Two patients remain alive and free of disease 41 and 38 months after initiation of therapy.
  • CONCLUSION: For patients with potentially operable MPM, the availability of active and well-tolerated chemotherapy regimens, the fact that extrapleural pneumonectomy can be safely performed after neoadjuvant chemotherapy in an experienced center, and the promising results regarding survival in our pilot study warrant further investigation of the role of neoadjuvant chemotherapy in a multimodality strategy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Pneumonectomy. Survival Rate

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Jan 20;23(3):655; author reply 655 [15659523.001]
  • (PMID = 15337794.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Small GR, Nicolson M, Buchan K, Broadhurst P: Pericardial malignant mesothelioma: a latent complication of radiotherapy? Eur J Cardiothorac Surg; 2008 Apr;33(4):745-7
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pericardial malignant mesothelioma: a latent complication of radiotherapy?
  • Pericardial diseases can be difficult to differentiate from myocardial conditions.
  • Diagnosis can be challenging and often requires the use of different imaging modalities.
  • Post-embolectomy she developed cardiac failure.
  • Three months previously an acellular, sterile pericardial effusion had been drained.
  • Adjuvant chemotherapy and radiotherapy were administered.
  • Cardiac MRI demonstrated thickened pericardium.
  • Histology revealed pericardial epithelioid malignant mesothelioma.
  • 18-FDG-PET CT post-operatively was negative in the pericardium and pleura.
  • Chemotherapy with pemetrexed and carboplatin was given.
  • Radiotherapy and asbestos exposure are both associated with pericardial mesothelioma and the aetiology in this case was not clear.
  • The condition carries a poor prognosis and is invariable fatal although newer chemotherapeutic regimens have prolonged survival times.
  • [MeSH-major] Breast Neoplasms / radiotherapy. Heart Neoplasms / etiology. Mesothelioma / etiology. Neoplasms, Radiation-Induced / etiology. Pericardium
  • [MeSH-minor] Diagnosis, Differential. Fatal Outcome. Female. Humans. Middle Aged. Pericarditis, Constrictive / etiology. Radiotherapy / adverse effects

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18280176.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Loggie BW: Malignant peritoneal mesothelioma. Curr Treat Options Oncol; 2001 Oct;2(5):395-9
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peritoneal mesothelioma.
  • This paper summarizes the author's thoughts about the use of cytoreductive surgery combined with intraperitoneal hyperthermic chemotherapy (CS-IPHC) for treatment of peritoneal malignant mesothelioma.
  • Pleural malignant mesotheliomas are by far more common (about ten- to thirty-fold) than the peritoneal variants (2.2 cases per 1 million in the US).
  • Other locations (pericardium, tunica vaginalis) are very rare.
  • It is well known that chemotherapy for mesothelioma is largely unsatisfactory, and measurement of treatment responses can be difficult.
  • Single agent responses are all less than 20% with currently available agents for systemically administered drugs.
  • Multiple drug combinations are typically more toxic, and have yielded little consistent demonstrable benefit with major studies reporting median survivals consistently under a year.
  • With peritoneal malignant mesothelioma, malignant ascites is a common presentation and a major factor in disease-related morbidity and mortality.
  • Interperitoneal administration of agents is attractive, but drug distribution is an issue, as are response rates and durability.
  • Multiple treatments are required; further, all neoplasms with peritoneal dissemination are typically understaged by current radiologic tests (CT, MRI), and the variable uptake of sugar by the small bowel limits the use of positron-emission tomography (PET) imaging for peritoneal malignant mesothelioma.
  • Also, symptoms of bowel obstruction are not uncommon, and any mechanical component of obstruction will not improve with any form of chemotherapy.
  • 2) tumor debulking, as possible, and treatment of mechanical obstruction as well as prevention of impending obstruction by resection or bypass; and 3) preparation for the use of intra-operative hyperthermic chemotherapy perfusion.
  • This approach has been associated with rapid clinical symptom improvement, as well as a reliable and durable resolution of ascites with a single therapy.
  • The inability to provide effective systemic therapy to maintain or consolidate these gains is problematic.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hyperthermia, Induced. Mesothelioma / therapy. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Ascites / etiology. Combined Modality Therapy. Diagnostic Imaging. Digestive System Surgical Procedures. Epidemiologic Methods. Humans. Infusions, Parenteral. Intestinal Obstruction / etiology. Remission Induction. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Jul 15;60(14):3696-700 [10919635.001]
  • [Cites] Lancet. 2001 Feb 10;357(9254):444-5 [11273069.001]
  • [Cites] Perfusion. 1999 Mar;14(2):141-5 [10338326.001]
  • [Cites] Am Surg. 2000 Jun;66(6):561-8 [10888132.001]
  • [Cites] Eur J Surg Oncol. 2001 Feb;27(1):65-73 [11237495.001]
  • [Cites] Am Surg. 1997 Feb;63(2):137-43 [9012427.001]
  • [Cites] Cancer Treat Res. 1996;81:193-211 [8834586.001]
  • [Cites] Ann Surg Oncol. 1999 Sep;6(6):582-90 [10493628.001]
  • [Cites] Anticancer Res. 1999 May-Jun;19(3B):2317-21 [10472351.001]
  • [Cites] J Cell Biochem. 1999 Dec;76(2):181-8 [10618635.001]
  • [Cites] Cancer J Sci Am. 1997 May-Jun;3(3):174-9 [9161783.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):358-63 [10640968.001]
  • [Cites] J Surg Oncol. 2000 Sep;75(1):55-8 [11025463.001]
  • [Cites] JAMA. 1998 Jan 28;279(4):292-5 [9450713.001]
  • (PMID = 12057102.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


13. Kao SC, Reid G, Lee K, Vardy J, Clarke S, van Zandwijk N: Malignant mesothelioma. Intern Med J; 2010 Nov;40(11):742-50
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma.
  • Malignant mesothelioma (MM) is an aggressive tumour that commonly affects the mesothelial surfaces of the pleural and peritoneal cavities, and occasionally, the tunica vaginalis and the pericardium.
  • Diagnosis of MM can be difficult.
  • Definitive pathological diagnosis is required and it often requires an experienced pathologist to differentiate MM from other benign or malignant processes.
  • Treatment of MM requires a multidisciplinary approach, regardless of palliative or curative intent.
  • Treatment options, such as surgery, chemotherapy, radiotherapy and active symptom control or a combination of these, may be used.
  • Further research is needed to advance the therapeutic options for MM, and strategies to realize personalisation of therapy through discovery of predictive markers.
  • [MeSH-major] Asbestos / toxicity. Environmental Exposure / adverse effects. Mesothelioma / epidemiology. Mesothelioma / etiology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Internal Medicine Journal © 2010 Royal Australasian College of Physicians.
  • (PMID = 20298508.001).
  • [ISSN] 1445-5994
  • [Journal-full-title] Internal medicine journal
  • [ISO-abbreviation] Intern Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


14. Nakano T: [Malignant mesothelioma--diagnosis and treatment strategies]. Gan To Kagaku Ryoho; 2006 Sep;33(9):1215-20
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant mesothelioma--diagnosis and treatment strategies].
  • Malignant mesothelioma originates from the mesothelial cells of the pleural and peritoneal cavities as well as the pericardium and tunica vaginalis, which is a devastating neoplasm with a strong etiological relationship with asbestos exposure.
  • Given the disappointing results of the single standard therapeutic modality, the combination of extrapleural pneumonectomy, chemotherapy, and radiotherapy has been attempted in order to reduce local recurrence and distal spread.
  • Chemotherapy using new antimetabolite agents in combination with platinum compounds is useful for palliation and can improve both survival and quality of life compared with single-agent cisplatin.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mediastinal Neoplasms / diagnosis. Mediastinal Neoplasms / therapy. Mesothelioma / diagnosis. Mesothelioma / therapy
  • [MeSH-minor] Asbestos / adverse effects. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Clinical Trials, Phase III as Topic. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Administration Schedule. Humans. Interleukin-6 / biosynthesis. Pleural Neoplasms / diagnosis. Pleural Neoplasms / surgery. Pleural Neoplasms / therapy. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16969013.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Interleukin-6; 0W860991D6 / Deoxycytidine; 1332-21-4 / Asbestos; 7673326042 / irinotecan; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 18
  •  go-up   go-down


15. Scripcariu V, Dajbog E, Lefter L, Ferariu D, Pricop A, Grigoraş M, Dragomir C: [Malignant peritoneal mesothelioma]. Chirurgia (Bucur); 2006 Nov-Dec;101(6):641-6
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant peritoneal mesothelioma].
  • [Transliterated title] Mezoteliomul malign peritoneal.
  • Mesothelioma is a neoplasm originating from the mesothelial surface lining cells of the serous human cavities.
  • It may involve the pleura, less frequently the peritoneum rarely, the pericardium, the tunica vaginalis testis and ovarian epithelium.
  • A causal relationship between asbestos exposure and pleural, peritoneal and pericardial malign mesothelioma was suggested, the risk of cancer being correlated to cumulate exposure.
  • Studies from National Cancer Institute, USA, show that the malignant mesothelioma is a rare and aggressive asbestos related malignancy.
  • The symptomatology is insidious and poses difficult problems in diagnosis and treatment.
  • This paper presents the case of a 59 year old patient with malignant peritoneal mesothelioma who worked almost 40 years as an electrician, exposed to asbestos fibers.
  • It was performed surgical ablation of the tumor, splenectomy with favorable postoperative evolution, the patient being now under chemotherapy treatment.
  • [MeSH-major] Asbestos / adverse effects. Mesothelioma / etiology. Occupational Diseases / etiology. Peritoneal Neoplasms / etiology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Male. Middle Aged. Splenectomy. Tomography, X-Ray Computed. Treatment Outcome


16. Palumbo C, Bei R, Procopio A, Modesti A: Molecular targets and targeted therapies for malignant mesothelioma. Curr Med Chem; 2008;15(9):855-67
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular targets and targeted therapies for malignant mesothelioma.
  • Malignant mesothelioma is a highly invasive tumor originating from the mesothelial linings of the pleura, peritoneum and pericardium.
  • It is seldom amenable to surgical intervention and poorly responsive to radiotherapy, leaving chemotherapy as the main therapeutic option for most patients.
  • The development of effective drug regimens against mesothelioma has proven extremely difficult and a standard first-line treatment for patients with unresectable tumors has not been established until recently.
  • Despite the benefits obtained with this newly validated standard of care, which is based on the combination of pemetrexed and cisplatin, the prognosis for mesothelioma patients remains poor, median survival is still less than two years and more active treatments are urgently needed.
  • This article will focus on the molecular basis providing the rationale for targeted interventions against mesothelioma and will review targeted agents under evaluation as new potential therapeutic options for mesothelioma patients.
  • The agents targeting vascular endothelial growth factor signaling are of particular interest, due to the involvement of this pathway both in tumor angiogenesis and autocrine stimulation of mesothelioma cell growth.
  • Alternative approaches are based on inhibitors of the ubiquitin-proteasome pathway and of histone deacetylases which, notwithstanding the functional divergence of the corresponding targets, share the ability to determine a wide modulation of the cancer cell phenotype that can lead to cell cycle arrest, apoptosis and sensitization to different antineoplastic treatments.
  • A recombinant immunotoxin targeted to the membrane antigen mesothelin is an additional agent whose activity is being evaluated in mesothelioma patients.
  • [MeSH-major] Antineoplastic Agents / metabolism. Antineoplastic Agents / therapeutic use. Enzyme Inhibitors / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Mesothelioma / drug therapy. Mesothelioma / metabolism. Receptors, Growth Factor / metabolism. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. GPI-Linked Proteins. Histone Deacetylase Inhibitors. Histone Deacetylases / metabolism. Humans. Immunotoxins / therapeutic use. Membrane Glycoproteins / metabolism. Proteasome Endopeptidase Complex / metabolism. Proteasome Inhibitors. Ubiquitin / antagonists & inhibitors. Ubiquitin / metabolism

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18473795.001).
  • [ISSN] 0929-8673
  • [Journal-full-title] Current medicinal chemistry
  • [ISO-abbreviation] Curr. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / GPI-Linked Proteins; 0 / Histone Deacetylase Inhibitors; 0 / Immunotoxins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Glycoproteins; 0 / Proteasome Inhibitors; 0 / Receptors, Growth Factor; 0 / SS1(dsFv)PE38; 0 / Ubiquitin; 0 / Vascular Endothelial Growth Factor A; 0 / mesothelin; EC 3.4.25.1 / Proteasome Endopeptidase Complex; EC 3.5.1.98 / Histone Deacetylases
  • [Number-of-references] 216
  •  go-up   go-down


17. Vigneswaran WT, Stefanacci PR: Pericardial mesothelioma. Curr Treat Options Oncol; 2000 Oct;1(4):299-302
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pericardial mesothelioma.
  • Primary pericardial mesothelioma is a rare but lethal disease.
  • In most cases the diagnosis is made at autopsy or postoperatively.
  • Surgical resection remains the main treatment modality.
  • Most often the tumor invades the myocardium or the great vessels and therefore is at best palliative in relieving pericardial tamponade or constriction.
  • Addition of chemotherapy or radiation has been disappointing.
  • Newer therapeutic approaches for malignant pleural mesothelioma are likely to influence the treatment of pericardial mesothelioma in the future.
  • [MeSH-major] Heart Neoplasms / therapy. Mesothelioma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Humans. Pericardium / pathology. Radiotherapy. Survival Rate

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1995 Jul;222(1):78-86 [7618973.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1559-65 [8336195.001]
  • [Cites] J Nucl Med. 1987 Jul;28(7):1210-2 [3474368.001]
  • [Cites] Am Heart J. 1988 Jun;115(6):1321-2 [3376853.001]
  • [Cites] Am Heart J. 1992 Sep;124(3):802-3 [1514518.001]
  • [Cites] Ann Surg Oncol. 1995 May;2(3):214-20 [7641017.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5 [9869758.001]
  • [Cites] Am Rev Respir Dis. 1978 Aug;118(2):419-24 [697191.001]
  • [Cites] Ann Oncol. 1994 Sep;5(7):660-1 [7993848.001]
  • [Cites] J Cardiovasc Surg (Torino). 1994 Jun;35(3):261-7 [8040178.001]
  • [Cites] Cardiovasc Clin. 1976;7(3):257-69 [1000541.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2577-82 [10375105.001]
  • [Cites] Environ Res. 1980 Dec;23(2):270-81 [7472312.001]
  • [Cites] Tex Heart Inst J. 1994;21(2):170-4 [8061543.001]
  • [Cites] Chest. 1982 Apr;81(4):520-3 [7067523.001]
  • [Cites] Postgrad Med J. 1992 Feb;68(796):137-9 [1570257.001]
  • [Cites] Am Heart J. 1986 May;111(5):986-8 [3706117.001]
  • [Cites] Cancer. 1970 Oct;26(4):914-9 [5506612.001]
  • [Cites] Scand J Thorac Cardiovasc Surg. 1987;21(3):273-5 [3438724.001]
  • [Cites] Cancer Chemother Pharmacol. 1991;28(6):420-6 [1934246.001]
  • (PMID = 12057155.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 21
  •  go-up   go-down


18. Yu L, Gu TX, Shi EY, Xiu ZY, Fang Q: [Diagnosis and therapy of primary malignant tumors of the heart and pericardium]. Zhonghua Zhong Liu Za Zhi; 2009 Mar;31(3):230-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and therapy of primary malignant tumors of the heart and pericardium].
  • OBJECTIVE: To summarize and analyze the experience in diagnosis and treatment of primary malignant tumors of the heart and pericardium.
  • METHODS: The clinical data of 24 patients with malignant tumors of the heart and pericardium treated in our hospital between Jun.
  • RESULTS: All 24 patients received surgical treatment.
  • CONCLUSION: Echocardiography, CT, MRI, 3D-CT, CT of coronary artery and cardiac angiography are helpful for the diagnosis and selection of operation mode.
  • Histological examination is necessary for the final diagnosis.
  • Early diagnosis and surgical resection of the tumor as complete as possible, and combination with post-operative radiotherapy and/or chemotherapy may improve the survival of the patients.
  • [MeSH-major] Heart Neoplasms / diagnosis. Heart Neoplasms / surgery. Mesothelioma / diagnosis. Mesothelioma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Myxoma / diagnosis. Myxoma / surgery. Pericardium / surgery. Retrospective Studies. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615268.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


19. Hasegawa S, Tanaka F: Malignant mesothelioma: current status and perspective in Japan and the world. Gen Thorac Cardiovasc Surg; 2008 Jul;56(7):317-23
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma: current status and perspective in Japan and the world.
  • Malignant pleural mesothelioma (MPM) is associated with a poor prognosis; and to make things worse, its incidence is increasing throughout the world.
  • Surgical management of MPM is comprised of two aspects: diagnosis and resection.
  • There are two types of surgical resection for MPM.
  • Pleurectomy/decortication (P/D) involves removal of as much of the visceral, parietal, and pericardial pleura and the tumor as possible without removing the underlying lung.
  • EPP comprises en bloc resection of visceral, parietal, and pericardial pleura and adjacent components such as ipsilateral lung, pericardium, and diaphragm, without opening the pleural cavity.
  • EPP was considered a highly dangerous procedure with a surgical mortality of more than 30% decades ago, but its current operative mortality/morbidity rates are 4%-9% and 60%, respectively.
  • In this context, combination therapy with surgery plus chemotherapy and/or radiotherapy is currently considered the standard treatment for patients with respectable MPM.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy. Thoracic Surgical Procedures
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Adjuvant. Humans. Japan. Laparoscopy. Mediastinoscopy. Neoplasm Staging. Pneumonectomy. Radiotherapy, Adjuvant. Thoracoscopy. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cardiothorac Surg. 1999 Dec;16(6):619-23 [10647830.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2629-30 [12860935.001]
  • [Cites] AJR Am J Roentgenol. 1999 Apr;172(4):1039-47 [10587144.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Jul;128(1):138-46 [15224033.001]
  • [Cites] Chest. 1995 Oct;108(4):1122-8 [7555126.001]
  • [Cites] Oncologist. 2007 Jul;12(7):850-63 [17673616.001]
  • [Cites] J Thorac Cardiovasc Surg. 2006 May;131(5):981-7 [16678579.001]
  • [Cites] Eur J Cardiothorac Surg. 2007 May;31(5):765-70; discussion 770-1 [17337201.001]
  • [Cites] Ann Thorac Surg. 2005 Dec;80(6):1988-92; discussion 1992-3 [16305830.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5 [9869758.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Oct;122(4):788-95 [11581615.001]
  • [Cites] Radiology. 2006 Nov;241(2):589-94 [17005770.001]
  • [Cites] Eur J Radiol. 2007 Dec;64(3):356-66 [17954021.001]
  • [Cites] Chest. 1997 Jan;111(1):106-9 [8996002.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):389-93 [8319170.001]
  • [Cites] Interact Cardiovasc Thorac Surg. 2008 Feb;7(1):102-6 [18048410.001]
  • [Cites] Chest. 2003 Feb;123(2):551-61 [12576380.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1183-5 [15451229.001]
  • [Cites] J Thorac Oncol. 2006 Feb;1(2):175-6 [17409850.001]
  • [Cites] Br J Cancer. 1998 Mar;77(6):907-12 [9528833.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1172-8 [8501504.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S27-32 [15950796.001]
  • [Cites] Ann Surg Oncol. 1996 Sep;3(5):489-94 [8876892.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S25-6 [15950795.001]
  • [Cites] J Clin Oncol. 1999 Jan;17 (1):25-30 [10458214.001]
  • [Cites] J Thorac Cardiovasc Surg. 2005 Sep;130(3):905-6 [16153957.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S71-4 [15950805.001]
  • [Cites] Br J Cancer. 2002 Feb 1;86(3):342-5 [11875695.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Apr;29(4):579-84 [16495068.001]
  • [Cites] Ann Thorac Surg. 2004 Nov;78(5):1774-6 [15511473.001]
  • [Cites] J Thorac Imaging. 2006 May;21(2):146-53 [16770231.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1224-30 [11571736.001]
  • [Cites] Lancet. 2005 Jul 30-Aug 5;366(9483):397-408 [16054941.001]
  • [Cites] Am J Ind Med. 2006 Jan;49(1):1-7 [16362942.001]
  • [Cites] Ann Surg Oncol. 2007 Apr;14(4):1249-53 [17066226.001]
  • [Cites] Ann Thorac Surg. 2006 Dec;82(6):2337; author reply 2337-8 [17126172.001]
  • [Cites] Lung Cancer. 2001 Jan;31(1):57-65 [11162867.001]
  • [Cites] Kyobu Geka. 2007 Jan;60(1):19-24 [17249533.001]
  • [Cites] Ann Thorac Surg. 2007 Nov;84(5):1685-92; discussion 1692-3 [17954086.001]
  • [Cites] J Nucl Med. 2007 Sep;48(9):1449-58 [17704250.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3451-7 [15337794.001]
  • [Cites] J Thorac Oncol. 2007 Oct;2(10):957-65 [17909360.001]
  • [Cites] Lung Cancer. 2001 Nov;34(2):279-87 [11679187.001]
  • [Cites] AJR Am J Roentgenol. 1990 Mar;154(3):487-92 [2106209.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Jan;29(1):14-9 [16343925.001]
  • [Cites] Thorax. 2007 Nov;62 Suppl 2:ii1-ii19 [17965072.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 Jun;133(6):1414-8 [17532931.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 1997 Oct;9(4):367-72 [9352954.001]
  • [Cites] Eur J Cardiothorac Surg. 1997 Feb;11(2):210-3 [9080144.001]
  • [Cites] Lung Cancer. 2007 Aug;57 Suppl 2:S24-9 [17686442.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):640-5 [16751058.001]
  • (PMID = 18607677.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 60
  •  go-up   go-down


20. Sterman DH, Albelda SM: Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma. Respirology; 2005 Jun;10(3):266-83
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma.
  • Malignant mesothelioma is an insidious neoplasm arising from the mesothelial surfaces of the pleural and peritoneal cavities, the pericardium, or the tunica vaginalis.
  • The predominant cause of malignant mesothelioma is inhalational exposure to asbestos, although evidence is increasing to support the hypothesis that simian virus-40 virus plays a role in cocarcinogenesis.
  • Preliminary data suggests that a soluble form of mesothelin could serve as a serum marker for established and early cases of mesothelioma.
  • Positron emission tomography with 18-fluorodeoxyglucose in conjunction with computed tomograhy scanning has improved preoperative imaging and staging.
  • For the first time, there is now evidence that some treatments are increasing the quality and quantity of life for patients with mesothelioma.
  • Chemotherapy, with the new multi-targeted antifolate drug Pemetrexed, combined with cisplatin, has shown superior survival rates in a large phase III trial when compared to cisplatin alone.
  • Multimodality treatment programs that combine surgical cytoreduction with novel forms of radiation therapy and more effective chemotherapy combinations may offer significant increases in survival for certain subgroups of mesothelioma patients.
  • Innovative palliative approaches have proved successful in alleviation of the significant symptoms experienced by many mesothelioma patients.
  • Experimental treatments such as immunotherapy and gene therapy present a window of hope for all mesothelioma patients, and in the future, may be combined with 'standard therapy' in multimodality protocols.
  • Over the past decade, significant advances have been made on several fronts that have improved the ability to diagnose a stage, define prognosis, and treat malignant pleural mesothelioma.
  • [MeSH-major] Mesothelioma. Pleural Neoplasms
  • [MeSH-minor] Combined Modality Therapy. Global Health. Humans. Incidence. Prognosis


21. Watanabe S, Shimokawa S, Sakasegawa K, Nakamura Y, Sakata R: [Surgical treatment for malignant pleural mesothelioma in eight cases]. Kyobu Geka; 2000 Dec;53(13):1101-4
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment for malignant pleural mesothelioma in eight cases].
  • Between 1987 and March 2000, we have operated on eight patients for malignant mesothelioma which consisted of four of localized type and four of diffuse type.
  • We have aggressively resected mesothelioma combined with chemotherapy whether the tumor was primary or recurrent, and concluded the following.
  • 1) In localized malignant mesothelioma, en-bloc primary tumor resection was possible and additional resection for recurrence was effective and useful for long time survival.
  • 2) In diffuse malignant mesothelioma, complete tumor resection was impossible to even perform pleuropneumonectomy accompanied with partial resection of pericardium and diaphragm and, therefore, the prognosis was poor in four patients and all died around one year.
  • 3) Because recurrent pattern for localized type was diffuse type, diagnosis and surgical treatment in early stage was essential for long time survival.
  • [MeSH-major] Mesothelioma / surgery. Pleural Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Diaphragm / surgery. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Pericardium / surgery. Pleura / surgery. Pneumonectomy. Prognosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11127555.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


22. Hosaka M, Ohde Y, Nakagawa K, Okumura T, Kameya T, Kondo H: Malignant pleural mesothelioma in a 14-year-old boy with right aortic arch. Jpn J Thorac Cardiovasc Surg; 2006 Oct;54(10):458-61
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pleural mesothelioma in a 14-year-old boy with right aortic arch.
  • We report successful surgery for malignant pleural mesothelioma (MPM) in a 14-year-old boy with right aortic arch.
  • Pleural biopsy by video-assisted thoracic surgery yielded a diagnosis of MPM, epithelial type.
  • As the disease was not changed after combination chemotherapy with three cycles of cisplatin and gemcitabine, we performed left extrapleural pneumonectomy, including resection of the pericardium and diaphragm for MPM, and aortopexy for right aortic arch.
  • [MeSH-major] Aorta, Thoracic / abnormalities. Mesothelioma / surgery. Pleural Neoplasms / surgery

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1988 Aug 15;62(4):838-47 [3293765.001]
  • [Cites] Chest. 1995 Oct;108(4):1122-8 [7555126.001]
  • [Cites] Cancer. 1972 Nov;30(5):1216-8 [5083060.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5 [9869758.001]
  • [Cites] Pediatr Pathol. 1992 May-Jun;12(3):333-47 [1384016.001]
  • [Cites] Radiology. 1991 Apr;179(1):100-2 [2006258.001]
  • [Cites] Tumori. 2002 Jan-Feb;88(1):1-9 [12004841.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3451-7 [15337794.001]
  • [Cites] Med Pediatr Oncol. 1981;9(4):367-73 [6790917.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • (PMID = 17087330.001).
  • [ISSN] 1344-4964
  • [Journal-full-title] The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi
  • [ISO-abbreviation] Jpn. J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


23. Anão AO, Gil V, Trabulo M, Ribeiras R, Ferreira MM, Nogueira M, Seabra-Gomes R: [Primary mesothelioma of the pericardium: a clinical case]. Rev Port Cardiol; 2001 Nov;20(11):1125-30
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary mesothelioma of the pericardium: a clinical case].
  • [Transliterated title] Mesotelioma primário do pericárdio: um caso clínico.
  • Medical therapy was initiated with no clinical benefit.
  • The intraoperatory examination revealed a thick pericardium adhering to the epicardium without a clear separation between them.
  • A diagnosis of primary pericardial mesothelioma was made after histological evaluation.
  • Despite its rarity, this diagnosis should be considered in cases with rapid evolution of constrictive or effusive-constrictive pericarditis.
  • The prognosis for pericardial mesothelioma is poor due to its late diagnosis, the difficulty of surgical excision and poor response to radio- or chemotherapy.
  • [MeSH-major] Heart Neoplasms / diagnosis. Mesothelioma / diagnosis
  • [MeSH-minor] Adult. Humans. Male. Pericardium

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11826704.001).
  • [ISSN] 0870-2551
  • [Journal-full-title] Revista portuguesa de cardiologia : orgão oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology
  • [ISO-abbreviation] Rev Port Cardiol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


25. Ponce Lorenzo J, Giménez Ortiz A, Aparisi Aparisi F, Fleitas Kanonnikoff T, Montalar Salcedo J: [Peritoneal mesothelioma: an inusual clinical presentation in a patient without exposure to asbestos]. An Med Interna; 2007 Feb;24(2):81-3
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Peritoneal mesothelioma: an inusual clinical presentation in a patient without exposure to asbestos].
  • [Transliterated title] Mesotelioma peritoneal: una presentación clínica inusual en un paciente sin exposición al asbesto.
  • Malignant mesothelioma is an insidious neoplasm arising from the mesotelial surfaces, of the pleural and peritoneal cavities, the tunica vaginalis, or the pericardium.
  • We present a rare case of primary malignant mesothelioma of the peritoneum in a 64 year old man without history of inhalation exposure to asbestos.
  • Positron emission tomography combined with computed tomography (PET/TC) was useful for a supporting diagnosis and to determine the extension.
  • The patient received treatment with systemic palliative chemotherapy, cisplatin-pemetrexed.
  • After three cycles, partial response was observed, but the evolution was fatal due to secondary toxicity of chemotherapy.
  • [MeSH-major] Mesothelioma / diagnosis. Peritoneal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17590095.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


26. Treasure T, Sedrakyan A: Pleural mesothelioma: little evidence, still time to do trials. Lancet; 2004 Sep 25-Oct 1;364(9440):1183-5
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleural mesothelioma: little evidence, still time to do trials.
  • CONTEXT: The incidence of malignant pleural mesothelioma is increasing throughout most of the world.
  • Desperation by patients and doctors has driven a search for effective treatments.
  • STARTING POINT: David Sugarbaker is the world's leading proponent of extrapleural pneumonectomy (EPP), an operation in which all the pleura is removed with the lung, pericardium, and diaphragm.
  • Although EPP as part of trimodality therapy (preoperative chemotherapy and postoperative radiation) is thought to be the best that can be offered and is regarded as the standard of care for selected patients given the morbidity associated with it, evidence for benefit is needed to justify its wider use.
  • WHERE NEXT? With the increase in the number of cases there is increasing awareness of the disease, leading to earlier diagnosis, and an expectation that something must be done.
  • Survival is short and the treatments on offer are onerous.
  • ) is to find evidence of effectiveness to avoid futile and distressing treatment when possible.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Humans. Pneumonectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15451229.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 34
  •  go-up   go-down


27. Rosenthal R, Langer I, Dalquen P, Marti WR, Oertli D: Peritoneal mesothelioma after environmental asbestos exposure. Swiss Surg; 2003;9(6):311-4
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal mesothelioma after environmental asbestos exposure.
  • Mesothelioma are primary malignant neoplasms of the serous membranes.
  • They usually involve the pleura and rarely the pericardium, the peritoneum and the tunica vaginalis testis.
  • This report of a patient from Anatolia with peritoneal mesothelioma after environmental exposure outlines the importance of considering this pathology in the differential diagnosis of a Turkish patient presenting with ascites.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asbestos / adverse effects. Asbestosis / drug therapy. Environmental Pollutants / adverse effects. Mesothelioma / drug therapy. Peritoneal Neoplasms / drug therapy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14725101.001).
  • [ISSN] 1023-9332
  • [Journal-full-title] Swiss surgery = Schweizer Chirurgie = Chirurgie suisse = Chirurgia svizzera
  • [ISO-abbreviation] Swiss Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Environmental Pollutants; 1332-21-4 / Asbestos; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


28. Sonoda S, Kumagawa Y, Inada E: A case of cardiac herniation after extrapleural pneumonectomy for malignant thymoma. J Anesth; 2010 Dec;24(6):926-9
Hazardous Substances Data Bank. DOPAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of cardiac herniation after extrapleural pneumonectomy for malignant thymoma.
  • A 44-year-old man underwent radical thymectomy for malignant thymoma 5 years ago.
  • He subsequently underwent right extrapleural pneumonectomy because a right pleural metastatic lesion had developed.
  • Emergent re-thoracotomy was performed and the heart was found to be malrotated and herniated from an upper defect of the pericardial patch in the right thoracic cavity.
  • The heart was returned to the pericardium and the defect was covered with a pericardial patch.
  • The incidence of cardiac herniation after extrapleural pneumonectomy following chemotherapy for malignant pleural mesothelioma has been reported to be around 3%.
  • [MeSH-minor] Adult. Anesthesia, General. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Cardiotonic Agents / administration & dosage. Cardiotonic Agents / therapeutic use. Dopamine / administration & dosage. Dopamine / therapeutic use. Electrocardiography. Humans. Male. Monitoring, Intraoperative. Respiration, Artificial. Supine Position. Thoracotomy

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Hernia.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 2007 Sep;73(9):906-8 [17939424.001]
  • [Cites] J Thorac Cardiovasc Surg. 1970 Mar;59(3):443-6 [5415089.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Jul;128(1):138-46 [15224033.001]
  • [Cites] J Thorac Cardiovasc Surg. 1979 Oct;78(4):623-5 [480972.001]
  • [Cites] Anaesth Intensive Care. 2005 Jun;33(3):403-9 [15973927.001]
  • [Cites] Chest. 2000 Apr;117(4):1184-5 [10767257.001]
  • [Cites] Thorax. 1974 Sep;29(5):545-52 [4428454.001]
  • [Cites] Anesth Analg. 1986 Oct;65(10):1085-8 [3752560.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 Jan;19(1):89-91 [11163569.001]
  • [Cites] J Thorac Imaging. 2007 Aug;22(3):280-2 [17721344.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Apr;29(4):579-84 [16495068.001]
  • [Cites] Acta Anaesthesiol Scand. 1992 Nov;36(8):842-5 [1466225.001]
  • [Cites] Ann Surg. 1948 Nov;128(5):1012-4 [17859240.001]
  • [Cites] Anesthesiology. 1984 Apr;60(4):362-4 [6703392.001]
  • (PMID = 20737279.001).
  • [ISSN] 1438-8359
  • [Journal-full-title] Journal of anesthesia
  • [ISO-abbreviation] J Anesth
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cardiotonic Agents; VTD58H1Z2X / Dopamine
  •  go-up   go-down


29. Hassan R, Ho M: Mesothelin targeted cancer immunotherapy. Eur J Cancer; 2008 Jan;44(1):46-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mesothelin is a tumour differentiation antigen that is normally present on the mesothelial cells lining the pleura, peritoneum and pericardium.
  • It is, however, highly expressed in several human cancers including malignant mesothelioma, pancreatic, ovarian and lung adenocarcinoma.
  • The limited mesothelin expression in normal tissues and high expression in many cancers makes it an attractive candidate for cancer therapy.
  • These ongoing clinical trials will help define the utility of mesothelin as a target for cancer therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cancer Vaccines. Immunotherapy / methods. Membrane Glycoproteins / drug effects. Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / therapeutic use. GPI-Linked Proteins. Genetic Vectors / therapeutic use. Humans. Listeria monocytogenes

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2006 Jul;6(7):559-65 [16794638.001]
  • [Cites] Gynecol Oncol. 2007 Jun;105(3):563-70 [17400285.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4547-51 [12907630.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1418-28 [14576474.001]
  • [Cites] BMC Dev Biol. 2003 Apr 7;3:2 [12697065.001]
  • [Cites] Lancet. 2003 Nov 15;362(9396):1612-6 [14630441.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):9190-8 [14676194.001]
  • [Cites] Hum Pathol. 2004 Mar;35(3):357-66 [15017593.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42 [15217923.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3a):1327-35 [15274292.001]
  • [Cites] J Exp Med. 2004 Aug 2;200(3):297-306 [15289501.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13832-7 [15365184.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Int J Cancer. 1992 Feb 1;50(3):373-81 [1735605.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):259-68 [1599018.001]
  • [Cites] Int J Cancer. 1992 Jun 19;51(4):548-54 [1351045.001]
  • [Cites] J Biol Chem. 1994 Jan 14;269(2):805-8 [8288629.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40 [8552591.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):669-74 [9435250.001]
  • [Cites] Nat Biotechnol. 1999 Jun;17(6):568-72 [10385321.001]
  • [Cites] Gene Ther. 2005 Jan;12(2):187-93 [15526007.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3814-20 [15897581.001]
  • [Cites] J Nucl Med. 2005 Jul;46(7):1201-9 [16000290.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):243-7 [16082249.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6342-51 [16144939.001]
  • [Cites] Am J Clin Pathol. 2005 Dec;124(6):838-45 [16416732.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):447-53 [16428485.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):827-31 [16467095.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4695-701 [16899620.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4983-8 [16914588.001]
  • [Cites] Mol Cancer. 2006;5(1):50 [17067392.001]
  • [Cites] Hum Pathol. 2007 Jan;38(1):1-16 [17056092.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1571-5 [17332303.001]
  • [Cites] Oncogene. 1999 Dec 20;18(55):7860-72 [10630639.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(8):2902-6 [10733593.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):145-56 [11134207.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):27371-5 [11369781.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3862-8 [11751476.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3520-6 [12429643.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):150-8 [12548160.001]
  • [Cites] Mod Pathol. 2003 Mar;16(3):192-7 [12640097.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5144-9 [17785569.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):605-9 [12827615.001]
  • (PMID = 17945478.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC010510-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Cancer Vaccines; 0 / GPI-Linked Proteins; 0 / MORAb-009 monoclonal antibody; 0 / Membrane Glycoproteins; 0 / SS1(dsFv)PE38; 0 / mesothelin
  • [Number-of-references] 46
  • [Other-IDs] NLM/ NIHMS38546; NLM/ PMC2265108
  •  go-up   go-down


30. Fujimoto N, Gemba K, Wada S, Ono K, Fujii Y, Ozaki S, Ikeda T, Taguchi K, Kunitomo T, Kishimoto T: Malignant pericardial mesothelioma with response to chemotherapy. J Thorac Oncol; 2009 Nov;4(11):1440-1
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pericardial mesothelioma with response to chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Heart Neoplasms / drug therapy. Mesothelioma / drug therapy
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Echocardiography. Fatal Outcome. Female. Humans. Middle Aged. Pericardium. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19861909.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down






Advertisement